NCT04159441

Hepatotoxicity of Antituberculosis Therapy (HAT) Study

Hepatotoxicity of Antituberculosis Therapy in a Real-World Setting: an Observational Study in China

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 5,000 (estimated)
• Sponsor: Huashan Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Drug-induced liver injury (DILI) is a common side effect in antituberculosis therapy, which interuputs the treatment of TB and leads to a higher proportion of Multidrug-Resistence TB(MDR-TB).The study primalily aims to observe the proportion of DILI in antituberculosis therapy. Furthermore, the secondary objective is to study the proportion of liver injury of based liver disase,liver failure and adjustment of chemotherapy in the obersevational study.

Detailed description

Drug-induced liver injury (DILI) is a common side effect in antituberculosis therapy, which interuputs the treatment of TB and leads to a higher proportion of Multidrug-Resistence TB(MDR-TB).The study primalily aims to observe the proportion of DILI in antituberculosis therapy. Furthermore, the secondary objective is to study the proportion of liver injury of based liver disase,liver failure and adjustment of chemotherapy in the obersevational study.

Conditions

• Chemical and Drug Induced Liver Injury

Interventions

Type	Name	Description
OTHER	None intervetion	None intervetion

Timeline

• Start date: 2019-12-05
• Primary completion: 2020-12-05
• Completion: 2021-06-05
• First posted: 2019-11-12
• Last updated: 2019-11-12